/Lipoprotein Disorders and Cardiovascular Disease/ 4-u1.0-B978-1-4377-0398-6..00047-0..DOCPDF Chapter 47 4-u1.0-B978-1-4377-0398-6..00047-0 4-u1.0-B978-1-4377-0398-6..00047-0 4-u1.0-B978-1-4377-0398-6..00047-0--s0050 Lipoprotein Disorders and Cardiovascular Disease Part VI 4-u1.0-B978-1-4377-0398-6..00047-0--s0010 Preventive Cardiology hubpart 3 section Preventive Cardiology Part VI 4-u1.0-B978-1-4377-0398-6..00047-0 4-u1.0-B978-1-4377-0398-6..00047-0--s0010 Lipoprotein Disorders and Cardiovascular Disease 4-u1.0-B978-1-4377-0398-6..C2009-0-59734-6--p10 Lipoprotein Disorders and Cardiovascular Disease text/html; charset=ISO-8859-1 Lipoprotein Transport System Chapter 47 chapter bookContent 4-u1.0-B978-1-4377-0398-6..C2009-0-59734-6--p10 Lipoprotein Transport System 4-u1.0-B978-1-4377-0398-6..00047-0 4-u1.0-B978-1-4377-0398-6..C2009-0-59734-6--p10 4-u1.0-B978-1-4377-0398-6..00047-0 4-u1.0-B978-1-4377-0398-6..00046-9--bb0010 5 4-u1.0-B978-1-4377-0398-6..00047-0--s0010 Chapter 47 Braunwald's Heart Disease, 9th edition 978-1-4377-0398-6 Bonow 1st
Chapter 47 – Lipoprotein Disorders and Cardiovascular DiseaseJacques Genest,
Peter Libby
| | | LIPOPROTEIN TRANSPORT SYSTEM, 975| | | Biochemistry of Lipids, 975
| | | | Lipoproteins, Apolipoproteins, Receptors, and Processing Enzymes, 975
| | | | Lipoprotein Metabolism and Transport, 978
|
|
| | | LIPOPROTEIN DISORDERS, 982| | | Definitions, 982
| | | | Genetic Lipoprotein Disorders, 982
| | | | Triglyceride-Rich Lipoproteins, 983
| | | | High-Density Lipoproteins, 985
| | | | Secondary Causes of Hyperlipidemia and the Metabolic Syndrome, 985
|
|
| | | DRUGS THAT AFFECT LIPOPROTEIN METABOLISM, 986| | | Bile Acid–Binding Resins, 986
| | | | Hydroxymethylglutaryl–Coenzyme A Reductase Inhibitors (Statins), 987
| | | | Cholesterol Absorption Inhibitors, 987
| | | | Fibric Acid Derivatives (Fibrates), 987
| | | | Nicotinic Acid (Niacin), 988
| | | | Cholesteryl Ester Transfer Protein Inhibitors, 988
| | | | Fish Oils, 989
| | | | Phytosterols, 989
|
|
| | | CLINICAL TRIALS OF DRUGS AFFECTING LIPID METABOLISM, 989| | | Secondary Prevention and Acute Coronary Syndromes, 989
| | | | Treating High-Risk (Primary Prevention) Patients, 990
| | | | Trials of Drugs Other Than Statins, 991
|
|
| | | APPROACH TO …
|